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Objectives
 Describe federal and state laws pertaining to the prescribing and 
dispensing of opioid controlled medications 
 Discuss methods of validating a prescription for therapeutic 
appropriateness and approaches for the detection of prescriptions 
that are not medically appropriate or have been furnished by 
fraudulent means 
 Review and assess prescriptions for appropriateness, quantity 
limitations and other requirements for opioids in the treatment of 
acute and chronic management of pain
 Discuss the purpose and function of the Florida Prescription Drug 
Monitoring Program (PDMP) E-FORCSE in identifying potential 
diversion of controlled substances (CS)
 Provide comprehensive patient education on overdose symptoms, 
information on available treatment resources for opioid 
dependence, addiction, misuse or abuse, as well as naloxone 
counseling (storage, disposal, potential drug interactions, side 
effects)
Schedules of CS’s
Schedule Potential for Abuse Examples 
C-I
High – Medical use currently not 
accepted in the US
• Heroin
• Lysergic acid diethylamide (LSD)
• Ecstasy 
C-II
High – May lead to severe 
psychological or physical dependence 
• Hydromorphone 
• Methadone 
• Meperidine
• Oxycodone 
• Fentanyl
• Amphetamines 
• Methylphenidate 
C-III
Less than C-I or C-II’s – May lead to 
low-moderate psychological or 
physical dependence 
• Combination products containing <15 mg 
of hydrocodone per dosage unit
• Combination products containing ≤90 mg 
of codeine 
• Buprenorphine products 
• Ketamine 
• Anabolic steroids 
C-IV Low • Benzodiazepines
C-V Low
• Cough preparations containing ≤200 mg of 
codeine per 100 mL or per 100 g
Background 
 An average of 130 Americans die every day from an 
opioid overdose 
 In 2018:
 2 million people had an opioid use disorder 
 ~ 10.3 million people aged ≥12 misused opioids 
 The United States Department of Health and Human 
Services (HHS) developed a 5-point comprehensive 
strategy to address opioid abuse, dependence, and 
overdose 
National Institute on Drub Abuse: Florida Opioid Summary
HHS 5-point 
Comprehensive Strategy
National Institute on Drub Abuse: Florida Opioid Summary
Florida Opioid Prescribing 
Rates 
National Institute on Drub Abuse: Florida Opioid Summary
60.9 vs 58.7
Florida Drug Overdose 
Deaths 
National Institute on Drub Abuse: Florida Opioid Summary
CDC Combats Opioid Crisis
 Enhanced State Opioid 
Overdose Surveillance 
(ESOOS) Program
 Captures different types of 
data for both fatal and 
nonfatal overdoses
 2016: 12 states were funded 
 2017: additional 20 states and 
the District of Columbia were 
added 
 Every four months, ESOOS-
funded states report overdose 
data to CDC
www.cdc.gov/drugoverdose/data/prescribing/overdose-death-urbanicity
ESOOS Program
 Data collected via emergency department (ED) 
hospital billing system and synchronized surveillance 
data 
 Utilize standard diagnostics codes that categorize if the 
visit was for an overdose 
 Objective is to improve the timeliness of fatal and 
nonfatal opioid overdose data for action and response
 Establish an early warning system
 Integrates data from death certificates and medical 
investigations
 Shares findings with state and national stakeholders
www.cdc.gov/drugoverdose/data/prescribing/overdose-death-urbanicity
ESOOS Program Success
 Identified 700 deaths involving fentanyl analogs 
across 10 of the ESOOS states from July to 
December 2016
 Reported findings on opioid overdoses treated in 
the EDs in 16 of the ESOOS states from July 2016 
through September 2017, showed that ED visits 
for opioid overdoses increased 30% in all parts of 
the United States
www.cdc.gov/drugoverdose/data/prescribing/overdose-death-urbanicity
History
1970 1990 2010 2010 2013 2017 2018
Enactment of the 
CSA
↑ in OD deaths 
due to ↑
prescribing
Amendment to CSA 
allows for E-prescribing 
of opioids
↑ in OD deaths 
due to heroin
↑ in OD deaths due 
to use of synthetic 
opioids
HHS enacts 5-point 
strategy to combat 
opioid epidemic
House Bill 21
CSA: controlled substance act; OD: overdose; HHS: Health and Human Services
Federal Controlled 
Substance Laws
Controlled Substance Act 
 The CSA provides a mechanism for substances to be 
controlled 
 Establishes federal requirements regarding both illicit 
and licit CS 
 Designed to function in tandem with state controlled 
substance laws to make certain that pharmaceutical 
CS are prescribed, administered, and dispensed for a 
legitimate medical purpose 
Diversion Control Division: Title 21 United States Code (USC) Controlled Substance Act 
Controlled Substance Act 
Diversion Control Division: Title 21 United States Code (USC) Controlled Substance Act 
Manufacturers 
Distributors
PharmaciesPatients
Doctors Closed 
System 
Controlled Substance Act 
 The Drug Enforcement Administration (DEA) 
responsibility in regards to pharmaceutical CS: 
 Prevent diversion and abuse of CS while ensuring 
appropriate and uninterrupted supply to meet the 
patient’s legitimate medical, scientific, and research 
needs. 
Diversion Control Division: Title 21 United States Code (USC) Controlled Substance Act 
Valid Prescription 
Requirements 
 Prescription: an order for a medication which is 
dispensed to or for an ultimate user
 An Rx for a CS must be dated and signed on the date 
when it was issued 
 Must include:
United States Department of Justice: Pharmacist’s Manual CS Act 
Patient’s full name and address 
Practitioner’s full name, 
address, and DEA registration 
number 
Medication name 
Strength and dosage form 
Quantity prescribed 
Directions for use 
Number of refills authorized 
Valid Prescription 
Requirements 
 Rx must be written in ink or typewritten and manually 
signed by the practitioner on the date when issued 
 An Rx for a CS may only be issued by a physician, 
dentist, podiatrist, veterinarian, or mid-level 
practitioner acting in the usual course of professional 
practice and for a legitimate medical purpose  
United States Department of Justice: Pharmacist’s Manual CS Act 
Valid Prescription 
Requirements 
 Pharmacist’s role in validating CS prescriptions: 
 Responsible to exercise sound professional judgment 
when making a determination about the legitimacy of an 
Rx prior to dispensing medication 
 Responsible for ensuring Rx has been issued by an 
appropriately registered practitioner 
United States Department of Justice: Pharmacist’s Manual CS Act 
Electronic Prescriptions
 The DEA published an interim final rule for electronic 
Rxs for CS
 Became effective June 1st, 2010
 Provide practitioners with the option of writing Rxs for 
CS electronically 
 Allow pharmacies to receive, dispense, and archive 
these electronic Rxs
United States Department of Justice: Pharmacist’s Manual CS Act 
C-II Substances 
Requirements
C-II Substances
 Require a written Rx which must be manually signed by the 
practitioner or an electronic Rx meeting all of the DEA’s 
requirements 
 There is no federal time limit within which a C-II Rx must be 
filled after being signed by the practitioner 
 No federal limits with respect to the quantitates of medications 
dispensed via an Rx
 Oral orders are only permitted in emergent situations 
 Refills are prohibited 
United States Department of Justice: Pharmacist’s Manual CS Act 
C-II Substances
 Up to a 90-day supply of a C-II may be dispensed under the 
following conditions:
 Each Rx must be issued on a separate prescription blank 
 Must be issued for a legitimate medical purpose by an 
individual practicing under the course of professional practice 
 Rx must provide written instructions indicating the earliest 
date on which a pharmacy may fill each Rx 
 Allowed under State Laws
 Practitioner complies fully with all requirements under the CSA 
and state laws 
United States Department of Justice: Pharmacist’s Manual CS Act 
C-II Substances
 Rxs may be transmitted to the pharmacy by facsimile in 
order to expedite the filling of an Rx 
 The original Rx must be presented to the RPh and 
verified against the facsimile at the time the CS is 
dispensed 
United States Department of Justice: Pharmacist’s Manual CS Act 
C-II Substances
 Exceptions for C-II facsimile prescriptions:
 C-II narcotic CS to be compounded for the direct 
administration to a patient by parenteral, IV, IM, SQ, or 
intraspinal infusion 
 C-II’s for residents of Long Term Care Facilities 
 C-II’s for a patient enrolled in a hospice program 
United States Department of Justice: Pharmacist’s Manual CS Act 
C-II Dispensing 
Requirements  
 Required information for Rx labels:
 Date of filling 
 Pharmacy name and address 
 Rx number
 Patient’s name 
 Prescriber’s name 
 Directions for use and cautionary statements 
 “CAUTION: Federal law prohibits the transfer of this 
drug to any person other than the patient for whom it 
was prescribed”
United States Department of Justice: Pharmacist’s Manual CS Act 
C-II Dispensing 
Requirements 
 C-II’s may only be dispensed pursuant to a written Rx 
signed by the practitioner with the exception of an 
emergency situation 
 Emergency dispensing: immediate administration of 
the medication is necessary for proper treatment of 
the intended ultimate user and no alternative 
treatment is available 
United States Department of Justice: Pharmacist’s Manual CS Act 
C-II Emergency 
Dispensing
 Prescriber must provide a written and signed Rx to the 
pharmacy within seven days of Rx being phoned in and 
must contain “authorization for emergency dispensing” 
written with the date of the oral order  
 Rx must be limited to the amount needed to treat the 
patient during the emergency
 Order must be immediately reduced to writing by the RPh
and contain all information with the exception of the 
prescriber’s signature 
United States Department of Justice: Pharmacist’s Manual CS Act 
C-II Partial Dispensing
 C-II’s may be partially dispensed if the RPh is unable 
to supply the full quantity 
 Remaining portion may be dispensed within 72 hours of 
the first partial dispensing 
 RPh must notify prescribing practitioner if remaining 
portion cannot be filled within 72 hours 
 RPh must note quantity supplied on the front of the 
written Rx 
United States Department of Justice: Pharmacist’s Manual CS Act 
CIII-V Substances 
Requirements
CIII-V Substances
 Rx may be received via facsimile as long as the 
practitioner has manually signed the Rx 
 Rx may be dispensed pursuant to an oral Rx made by 
an individual practitioner and reduced to writing by 
the RPh
 May be transferred to another DEA registered 
pharmacy for the purpose of refill dispensing between 
pharmacies on a one time basis
United States Department of Justice: Pharmacist’s Manual CS Act 
CIII-V Substances
 Pharmacies sharing a real-time, on-line database may 
transfer up to the maximum refills permitted by law 
 Transfer of CIII-V must be communicated between 
two licensed RPhs
United States Department of Justice: Pharmacist’s Manual CS Act 
Dispensing of C-III & C-IV 
Refills
 C-III’s and C-IV’s may be refilled up to 5 times within 
6 months after the date of issue
 Required information to be recorded on the back of 
Rx:
 RPh’s initials 
 Date the Rx was refilled 
 Amount of medication dispensed on the refill 
United States Department of Justice: Pharmacist’s Manual CS Act 
Florida Controlled 
Substance Laws
Standards of Practice
 The Board of Pharmacy recognizes that it is 
important for the patients to be able to fill valid 
Rxs for CS
 RPhs should not fear disciplinary action for 
dispensing CS for a legitimate medical purpose 
in the usual course of professional practice
 Every patient’s situation is unique and Rxs for 
CS shall be reviewed accordingly
Florida Statue 64B16-27.831
Definitions – FL Law
 Valid Rx– An Rx is valid when it is based 
on a practitioner-patient relationship and 
when it has been issued for a legitimate 
medical purpose
 Invalid Rx– An Rx is invalid if the RPh
knows or has reason to know that the Rx 
was not issued for a legitimate medical 
purpose
Florida Statue 64B16-27.831
House Bill 21
 Effective July 1st, 2018
 Florida specific 
 Objective is to increase regulation, training, and 
reporting required when CS are prescribed and 
dispensed
 E-FORCSE®*
 Prescribing limitations
*Electronic-Florida Online Reporting of Controlled Substance Evaluation Program 
House Bill No. 21: Chapter 2018-13.p1-106
Defining Pain
Acute Pain Non-acute or Chronic Pain 
Normal, predicted, 
physiological, and time-
limited response to an 
adverse chemical, thermal, 
or mechanical stimulus 
associated with surgery, 
trauma, or acute illness
• Cancer, terminal condition, 
palliative care or serious traumatic 
injury with an Injury Severity Score 
(ISS) ≥9
• Chronic nonmalignant pain 
persisting beyond usual course of 
disease or injury OR pain persisting 
>90 days after surgery 
• Requires treatment plan
• Patients entered in CS 
agreement with prescriber
• Patients must be seen at least 
every 3 months 
• Patient may only have a single 
provider 
House Bill No. 21: Chapter 2018-13.p1-106
Application
Acute Pain Non-acute Pain 
• Limits an Rx for an opioid 
listed in C-II to 3 days
• Limit may be increased to 7 
days if determined to be 
medically necessary 
• Prescriber must have 
“ACUTE PAIN EXCEPTION” 
on the Rx
• Limits the dispensing of a 
CII-III medication in 
connection to a surgical 
procedure to a 14 day supply
• Limits do not apply to C-II 
medications for treatment of 
addiction
• Prescriber must indicate 
“NONACUTE PAIN” on an Rx for 
a C-II medication
• Patients treated for a traumatic
injury with an ISS of ≥9 must 
be concurrently prescribed an 
emergency opioid antagonist
• If this is not received, RPh 
should follow standard policy 
and procedures and contact 
prescriber
• Any changes should be 
promptly reduced to writing 
and properly annotated
House Bill No. 21: Chapter 2018-13.p1-106
Prescription Pads Sample
Assessing for Prescription 
Appropriateness 
Deciding for Prescription 
Appropriateness 
 Rx looks authentic and has all the information required 
by law 
 Perform prospective Drug Utilization Review 
 Assess drug, dose and duration
 Review the patient’s medication profile in your 
computer
 Review the PDMP report
Legible Prescription
 A written Rx for a CS must have the quantity of the 
medication prescribed in both textual (one, two, 
three, etc) and numerical (1,2,3, etc) formats
 Must be dated in one of the following ways:
 Numerical month/day/year format (ex: 1/1/2016)
 Abbreviated month written out (ex: Jan. 1, 2016)
 Month written out in whole (ex: January 1, 2016) 
Florida Statue 456.42
Deciding for Prescription 
Appropriateness 
 Speak with the prescriber
 Previous experience
 Converse and observe the behavior of the patient
 Patient’s medical history
 Clinical appropriateness and safety
 Quantity limitations and other requirements in the 
treatment of acute and chronic management of pain
Validating a Prescription
Corresponding Responsibility
 The responsibility for the proper prescribing and dispensing of CS 
is upon the prescribing practitioner, but a corresponding 
responsibility rests with the RPh who fills the Rx
 The law further states that any individual knowingly dispensing an 
invalid Rx for a CS will be subject to criminal penalties and 
administrative sanctions
CFR Section 1306.04
Validating a Prescription
 The process implemented by the RPh to determine that 
the Rx was issued for a legitimate medical purpose 
 Each Rx may require a different validation process and 
no singular process can be applied each situation
 A concern with validity does not mean the Rx should 
not be filled
Florida Statue 64B16-27.831
Validating a Prescription
 When validating an Rx:
 Neither a person or licensee must interfere with the 
exercise of the RPh’s independent professional judgment
 Communication with the patient should not be overheard 
by others
 If the RPh determines that concerns with validity cannot 
be resolved, the RPh must refuse to fill
Florida Statue 64B16-27.831
Refusal of CS Prescription
 Before the refusal of an Rx, the RPh shall do the 
following:
 Communicate with the patient or the patient’s 
representative 
 Contact the prescriber or the prescriber’s agent
 Access the PDMP to acquire information 
Florida Statue 64B16-27.831
Duty to Report
 If an RPh believes that a prescriber is involved in the 
diversion of CS, he/she must report the prescriber to the 
Department of Health
 This can be reported online at:
 www.floridahealth.gov/licensing-and-regulation/enforcement/index.html
Florida Statue 64B16-27.831
Federal and State 
Requirements for CII-CV
CII CIII-CV
Refills No refills allowed
5 within 6 months from date 
written 
Transfer of Rx 
Between 
Pharmacies
No transfers permitted
1 allowed (may transfer additional 
times to the maximum if within 
same common database)
Facsimile Rx 
Allowed
May be received in 
preparation, but original hard-
copy is required
Exceptions:
• Narcotic compounded for 
direct administration to 
patient
• LTCF/Hospice Patients
Yes
Federal and State 
Requirements for CII-CV
CII CIII-CV
Electronic Rx 
Allowed
Yes Yes
Partial Fills 
Allowed
Yes
• Remainder required within 
72 hrs
• For terminally ill patients and 
LTCF patients, Rx is good for 
60 days
Yes
• No restrictions as long as 
within total quantity and 6 
month limitation
Emergency 
Dispensing 
Limited to the amount needed 
to treat the patient 
• Dispensing is limited to a 72-
hour supply
Yes
Expiration Date
No expiration (FL law imposes 1 
year expiration on all Rx)
6 months from date written
Fraudulent Prescriptions
 Usually patients tend to come at the end of the day 
 RPh is extremely busy 
 Prescriber’s office is closed 
 Most drug abusers seek areas where communication 
and cooperation between healthcare professionals is 
minimal 
 The RPh should become familiar with CS that are 
popularly abused and resold on the streets
DEA Guidelines to Prescription Fraud. Florida Board of Pharmacy.
Prescription Drug Diversion: Fraudulent Tactics Utilized in the Community Pharmacy.
Types of Fraudulent 
Prescriptions
 Quantity altered: change “10” to “100” or “10” to “40”
 Adding refills or altering the directions
 Adding an additional medication to a legal Rx
 Changing medication: adding “ES” to Vicodin
 Individuals calling in their own Rx
 Forging call back number and using fictitious patient or 
physicians name and addresses
DEA Guidelines to Prescription Fraud. Florida Board of Pharmacy.
Prescription Drug Diversion: Fraudulent Tactics Utilized in the Community Pharmacy.
Fraudulent Prescriptions: 
Things to Look For
 Rx looks “too good”. The prescriber’s handwriting is too legible
 Quantities, directions, or dosages differ from usual medical usage
 Rx does not comply with acceptable standard abbreviations 
(directions that are written out)
 Rx appears to be photocopied
 Directions are written in full with no abbreviations
 Rx is written in different color inks or written in different 
handwriting
Diversion Techniques and 
Signs by Patients
 Changes in personality and/or appearance
 Claiming multiple allergies to alternative medications
 Aggressively complaining about a need for a 
medication
 Uses medical terminology with respect to their pain
 Requests specific generics or brands
 No clear diagnosis from the physician
 Frequently ask for early refills
Diversion Techniques by 
Prescribers
 Patients traveling long distances to see practitioner
 Practitioner prescribing excessive quantities of CS 
relative to the medical condition 
 Multiple medications within the same category or 
medication cocktails being prescribed 
 Examples: Narcotic pain killer + benzodiazepine + sleeping pill + 
codeine containing cough syrup + carisoprodol or any other combination
 Health care professionals prescribing outside their 
scope of practice
Diversion Techniques by 
Prescribers
 Physician’s note and diagnosis are similar for every 
patient 
 Lack of individualization
 Practitioner ignoring signs of abuse
 Patient’s appearance
 Requesting for specific CS
 Practitioner ignoring toxicology reports 
 Beware of nurses and non-medical staff calling in oral 
Rxs
Motivation for Diversion
 Money – financial gain
 Fear
 Stop blackmail 
 Sexual favors 
 Keep business going/co-independency
 Personal Use – self abuse 
Pharmacist Checklist to 
Prevent Diversion
 Type of medication prescribed (number of CNS 
depressants and stimulants)
 Duplicate therapy or duplicate therapeutic classes
 Strengths, quantity, and days supply of medication 
prescribed
 Number of physicians the patient is seeing
 Escalating doses, quantities, and/or strengths
 Method of payment by patient
 Look for documentation in patient record

E-FORCSE®
Overview
What is it?
•Electronic 
systems that 
digitally store, 
monitor, and 
analyze CS 
dispensing 
information
What data is 
collected?
• Patient info
• Prescriber info
•Dispenser info
• CII-V 
medications
Who can 
access data?
• Prescribers
• RPh
• Law 
enforcement
• State medical 
boards
E-FORCSE® Florida Department of Health
Structure of Legislation
E-FORCSE® Florida Department of Health
Data Reported to 
E-FORCSE®
 Prescribing practitioner name, federal DEA registration 
number, National Provider Identification (NPI), and date 
Rx written 
 Date Rx was filled and the method of payment
 Name, address, telephone number and date of birth 
(DOB) of patient for whom the Rx was written
Florida Statute 893.055(3)(a)(1-8)
Data Reported to 
E-FORCSE®
 Name, national drug code, quantity, and strength of CS
 Name, federal DEA registration number, and address of 
the pharmacy/location from which the CS was dispensed
 Name of pharmacy or practitioner (other than an RPh) 
dispensing the CS and the practitioner’s NPI identifier
 Other appropriate identifying information as determined 
by department rule
Florida Statute 893.055(3)(a)(1-8)
Healthcare Professional 
Responsibilities
 Must report to PDMP each time a CS in CII-V is dispensed
 All patients ≥16
 Including internet and mail order pharmacies and dispensing 
healthcare practitioners
 Report as soon thereafter as possible but no later than 
close of next business day after Rx dispensed
 Exceptions apply
 Dispenser must file a zero report if there are no 
transactions to report for that day
Florida Statute 893.055(3)(a)(1-8)
Zero Reports
 https://pmpclearinghouse.net 
 Confirmation email is sent to submitter
Healthcare Professional 
Responsibilities
 Those that never dispense CS in or into Florida are 
not required to report to E-FORCSE®
 Must notify E-FORCSE® in writing by submitting a 
“Notification of Exemption from Reporting Form”
 Must be renewed biennially on or before February 28 in 
odd years
 http://www.floridahealth.gov/statistics-and-data/e-
forcse/_documents/waiver-form-2014apr-distributed.pdf
Florida Statute 893.055(3)(a)(1-8)
Statutory Exceptions 
 Patients <16 
 C-V non-opioid medications 
 System is not operational 
 Requestor has technological or electrical failure
 Prescriber or dispenser shall document the reason 
for not consulting PDMP in patient’s record
 Shall not prescribe/dispense ≥3-day supply
Florida Statute 893.0551(8)(2)(b)
Reporting Exemptions
 All acts of administration: 
 Directly to patient 
 Hospital
 Nursing home, assisted-care facility, or rehabilitation center
 Ambulatory surgical center
 Hospice
 Intermediate care facility for the disabled
 Dispensing in the Florida Department of Corrections or 
ED of a licensed hospital
E-FORCSE® Florida Department of Health; S. 893.055(2)(a), F.S. 
Emergency Suspension 
from Reporting
 A reporting suspension waiver will be granted for the 
seven day reporting period 
 Once the state of emergency has been lifted, the 
dispenser must report the backlog of data as soon as 
possible to bring reporting current
DH8013-PDMP, 07/15Ïule 64K-1.004, F.A.C.
Reporting Noncompliance
 A dispenser who willfully and knowingly fails to report 
the dispensing of a CS medication, as required by 
section 893.055, F.S., commits a misdemeanor of 
the first degree
 Punishable by 775.082 or 775.083, F.S.
Florida Statute 775.082-775.083
Utilizing E-FORCSE®
Pharmacist Requirements
 An RPh must verify the identity of an individual 
prior to dispensing a CS medication
 Proper identification is issued by a state or the Federal 
Government containing the person’s photograph, printed 
name, and signature or a document considered 
acceptable under 8 C.F.R. s. 274a.2(b)(1)(v)(A) and (B)
8 C.F.R. s. 274a.2(b)(1)(v)(A) and (B)
Assessment of Rx using 
E-FORCSE®
 PDMP reports are only as good as they are entered
 Potential errors may include:
 Rx filled but not picked up yet
 Incorrect day supply
 Wrong date written
 Wrong doctor
 Patient name misspelled or multiple last names
 Wrong DOB or address 
E-FORCSE® Florida Department of Health
Assessment of Rx using 
E-FORCSE®
 If something does not look correct in PDMP, call the 
pharmacy who filled the Rx or prescriber in order to 
verify
 Example: An RPh looks at the PDMP and sees the patient 
had an Rx for alprazolam 2 mg, #300, one tab BID
• Steps to take: call pharmacy who filled Rx and verify the 
information found on PDMP
E-FORCSE® Florida Department of Health
PDMP Checklist
 Type of medications prescribed
 Duplicate therapy
 Strengths and quantities
 Number of physicians the patient is seeing
 Number of pharmacies the patient is using
 Is the patient using urgent care centers, convenience clinics, 
EDs, and/or dentists to obtain CS medications?
 Are patients getting medications filled early?
 Are the doses, quantities, and/or strengths escalating?
E-FORCSE® Florida Department of Health
Opioid Overdose, 
Prevention and 
Management 
Overdose
 On average, 130 Americans 
die each day from an opioid 
overdose
 Between 1999-2017, there 
were ~400,000 opioid 
overdose deaths 
 1990’s: increased 
prescribing of opioids 
 2010: rise in heroin 
overdose deaths 
 2013: synthetic opioid 
overdose deaths, 
specifically involving 
fentanyl
Opioid Overdose. Centers for Disease Control and Prevention. Updated December 19, 2018. Accessed December 20, 2019. 
Pathophysiology of Overdose
 Several receptors mediate the effects of opioids 
• Mu  analgesia, euphoria, constipation, respiratory depression, miosis 
• Kappa  analgesia, diuresis, dysphoria 
• Delta  analgesia, convulsions, anxiolysis 
 Opioid receptors are located in both the central and peripheral 
nervous system (brain, spinal cord and GI tract)
Schiller EY, Mechanic OJ. Opioid Overdose. StatPearls Publishing. 2019. Updated Mar 2, 2019. 
Opioid Mechanism of Action
 Potent agonism of the mu 
receptor by opioids results 
in a release of dopamine, 
blockade of pain 
transmission and a euphoric 
sensation via the reward 
pathway
 In the case of overdose, the 
opioid receptors located in 
the medulla are 
overwhelmed and can 
suppress respiratory drive 
to the point of cessation 
Opioid Pharmacokinetics
Normally, opioids undergo 
first order elimination
When opioid receptors are 
saturated, elimination is 
converted to zero order 
kinetics and small dose 
increases can change 
plasma concentration 
immensely 
Schiller EY, Mechanic OJ. Opioid Overdose. StatPearls Publishing. 2019. Updated Mar 2, 2019. 
Risk Factors for Overdose
 Individuals who are dependent on opioids for chronic pain
 Taking increasing doses of opioids for pain management
 High-dose opioids (> 50 MME/d) 
 Concomitant severe medical or psychiatric conditions (depression, 
HIV, lung/liver disease) 
 Combining opioids with alcohol or other sedatives 
 Male gender 
 Younger age 
 Household members taking opioids
 History of injection drug use
Schiller EY, Mechanic OJ. Opioid Overdose. StatPearls Publishing. 2019. Updated Mar 2, 2019. 
Morphine Milligram Equivalents
https://www.google.com/search?q=morphine+equivalents&rlz=1C1CHBF_enUS851US851&sxsrf=ACYBGNTGkCV6ihirn3pf1BsrwN5V3_NNDQ:1577560504349&source=lnms&tbm=isch&sa=X&ved=2ah
UKEwi4wOTrhtnmAhVqhOAKHXKLB1IQ_AUoAXoECAsQAw&biw=1368&bih=721&dpr=2#imgrc=0VJWrQ98axfilM:
• 15 mg oxycodone BID = 45 MME
• 30 mg oxycodone BID = 90 MME
• Percocet® 5/325 QID = 30 MME
• Percocet® 10/325 QID = 60 MME
• 2 mg PO q4h = 48 MME
High-dose opioids (> 50 MME/d) increase a patients risk of overdose  
Naloxone
Mechanism of Action
 Naloxone is a pure opioid antagonist that competes and displaces opioids at opioid 
receptor sites 
 Has stronger affinity than opioids at all opioid receptor subtypes, but most notably at 
the mu receptor 
 Specifically designed to only reverse overdose – while it still binds to opioid receptors, 
it will not produce a “high” or have any opioid-like effects
 Naloxone has no effect if opioids are not present 
Naloxone for Opioid Overdose: What Pharmacists Should Know. PharmacyTimes.Updated June 2016. Accessed December 20, 2019.
Naloxone Administration
 Naloxone is available to be administered via 2 routes:
 Intranasal 
A. Narcan® nasal spray 
B. Naloxone nasal spray with atomizer 
 Intramuscular
C. Evzio® auto-injector 
D. Naloxone injectable – IM or SC 
Naloxone Dosing 
Products Dose
Narcan® Nasal Spray 4 mg/0.1 mL 
Naloxone Nasal Spray 
with Atomizer
2 mg/2 mL
Evzio® Auto-injector 2 mg/0.4 mL
Naloxone for injection 0.4 mg/1 mL
Naloxone (Narcan®) Nasal Spray
 Requires no assembly, very simple 
to use
 Peel, Place, Press
 Peel back the tab to remove the 
device from the packaging 
 Hold nasal spray with your thumb on 
the bottom, and your middle and index 
fingers on either side of the nozzle 
 Tilt the person’s head back, support 
their head and place the tip of the 
nozzle into 1 nostril until your fingers 
touch the patient’s nose 
 Press the plunger firmly to administer 
the full dose and call 911 
 Repeat with the other nostril if the 
person does not respond in 2-3 
minutes
Family Health Centers of San Diego. Opioid Safety. https://www.fhcsd.org/opioid-safety/. Accessed December 20, 2019.
Naloxone Nasal Spray
 Requires assembly
 Pop off the yellow caps from either end 
of the syringe 
 Screw on the nasal atomizer to the tip of 
the syringe
 Remove the colored cap from the 
naloxone and insert into the barrel of the 
syringe, gently screwing them together
 Insert the white cone into the nostril and 
give a short, strong push on the end of 
the naloxone to administer 
 One half of the naloxone capsule 
should be administered into each 
nostril
 Repeat the above if the patient does not 
respond in 3 minutes 
Family Health Centers of San Diego. Opioid Safety. https://www.fhcsd.org/opioid-safety/. Accessed December 20, 2019.
Naloxone (IM)
 Administering injectable naloxone 
(either IM or SC) requires assembly
 First, remove the cap from the naloxone 
vial and uncover the needle 
 Insert the needle into the rubber stopper
 Invert the vial to withdrawal the full 
contents (1 mL) into the syringe 
 Inject naloxone into either the deltoid or 
quadricep muscle
 Naloxone can be injected through the 
clothing!
 Repeat the dose if the patient does not 
respond within 3-5 minutes 
Family Health Centers of San Diego. Opioid Safety. https://www.fhcsd.org/opioid-safety/. Accessed December 20, 2019.
Naloxone (Evzio®)
 No assembly and very simple to use
 The device is equipped with a voice instruction 
system to guide the user through the entire 
administration process
 Steps for use: 
 The auto-injector should be pulled from the 
outer case
 Firmly remove the red safety guard (the needle 
is housed within the black base) 
 Place the black end of the device against the 
middle of the outer thigh, press firmly and hold 
in place for 5 seconds (the needle will retract 
into the device when the dose is given)
 Can be administered through clothing
 If no response in 2-3 minutes, repeat the dose 
using a second auto-injector 
 Note: the Evzio® device makes a distinct 
clicking/hissing sound on administration – this is 
normal and indicates the device is working properly
Evzio. How to Use Evzio. https://evzio.com/patient/how-to-use-evzio/. Accessed December 20, 2019.
Storage and Disposal 
 Storage 
 Naloxone should be stored at room temperature in its original 
packaging 
 Should be kept away from children/pets, but always in a place 
that is quickly and easily accessible 
 Do not assemble naloxone until ready to administer, when 
applicable
 Disposal
• For intranasal dosage forms, the used 
naloxone can be discarded with other solid 
waste
• For injectable dosage forms, the used 
naloxone should be discarded of in a sharps 
container (this can be an empty laundry 
detergent bottle or thick/hard plastic 
container) 
Adapt Pharma Incorporation. Narcan (naloxone) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208411lbl.pdf. Accessed December 20, 2019.
Drug Interactions and Side 
Effects
 DDI’s
 Due to its action as an opioid antagonist, naloxone will have 
an interaction with any drug considered an opioid 
 Side effects
 Sudden opioid withdrawal symptoms:
 Body aches
 Diarrhea
 Tachycardia
 Fever
 Runny nose
 Sneezing
 Goose bumps
 Sweating
 Yawning
 Nausea/vomiting
 Nervousness 
 Restlessness
 Shivering
 Abdominal cramps
 Weakness 
 Hypertension 
Adapt Pharma Incorporation. Narcan (naloxone) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208411lbl.pdf. Accessed December 20, 2019.
Who Should be Given a 
Prescription for Naloxone?
 Title XXXII, Ch. 456.44 of Florida Pharmacy Law states: 
 EMERGENCY OPIOID ANTAGONIST.—For the treatment of pain related to a 
traumatic injury with an Injury Severity Score of 9 or greater, a 
prescriber who prescribes a Schedule II controlled substance listed in 
s. 893.03 or 21 U.S.C. s. 812 must concurrently prescribe an 
emergency opioid antagonist, as defined in s. 381.887(1).
 Patients who are considered to be “high risk” for opioid overdose:
 History of overdose or substance abuse 
 High opioid doses (> 50 MME/d) 
 Concurrent benzodiazepine use
 Sleep apnea 
 Pregnancy 
 Renal/hepatic disease 
 > 65 years old 
 Concomitant mental health conditions 
Dreiling J. The Validation of Controlled Drug Prescriptions in Florida. https://s3.amazonaws.com/EliteCME_WebSite_2013/f/pdf/RPFL02VCI18.pdf. Accessed December 20, 2019.
Recognizing an Overdose
 The “opioid overdose triad” is a combination of 3 signs and 
symptoms that can be used to identify an opioid overdose
Pinpoint pupils 
Unconsciousness 
Respiratory depression (slow, shallow breathing) 
 Other signs to look for include: 
Skin, lips and fingernails will be a bluish/purple color 
Choking sounds, or a snore-like gurgling noise 
Vomiting 
Slowed heart rate
Body is limp 
 The combination of opioids with alcohol and other CNS 
depressants increases the risk of death due to an overdose
Dreiling J. The Validation of Controlled Drug Prescriptions in Florida. https://s3.amazonaws.com/EliteCME_WebSite_2013/f/pdf/RPFL02VCI18.pdf. Accessed December 20, 2019.
How to Tell the Difference 
 It can sometimes be unclear whether a person is overdosing 
or is just extremely high 
 Always err on the side of caution and respond as if the 
person is experiencing an overdose 
 Whether or not the patient is responsive will help to 
determine if the patient is high versus overdosing 
High Overdosing
• Pinpoint pupils 
• Muscles are droopy/limp
• “Nodding out” 
• Slurred speech
• Might seem disoriented, but 
will respond to outside 
stimulus (noises, agitation)
• Pinpoint pupils 
• Loss of consciousness 
• Awake but unable to speak
• Skin/nail/lip color changes 
• Unresponsive
Recognizing Opioid Overdose. Harm Reduction Coalition. https://harmreduction.org/issues/overdose-prevention/overview/overdose-basics/recognizing-opioid-overdose/. Accessed December 20, 2019.
Responding to an Overdose
Call 911
Perform 
CPR
Administer 
naloxone
Stay until 
help 
arrives
Responding to an Overdose
 1. Call 911
 Opioid overdoses will still require professional medical 
assistance even if naloxone helps
 2. Support the patient’s breathing with CPR
 Ensure a clear airway 
 Place one hand on the patient’s chin, tilt head back and pinch 
the nose closed 
 Place mouth over patient’s mouth to make a seal and give 2 
slow breaths – the patient’s chest should rise 
 Give one breath every 5 seconds
Dreiling J. The Validation of Controlled Drug Prescriptions in Florida. https://s3.amazonaws.com/EliteCME_WebSite_2013/f/pdf/RPFL02VCI18.pdf. Accessed December 20, 2019.
Responding to an Overdose
 3. Administer naloxone when signs of an overdose are 
present 
 Naloxone should be given to restore respiratory drive
 4. Stay until help arrives
 You can expect naloxone to work within 3-5 minutes 
 Duration of action of naloxone is 30-90 minutes
 Patients should be placed on their side 
 Do not slap or forcefully stimulate patients as it may cause 
harm 
 Patients should not be placed in cold water, injected with 
speed to wake them up or be forced to vomit the ingested 
drug(s) 
Dreiling J. The Validation of Controlled Drug Prescriptions in Florida. https://s3.amazonaws.com/EliteCME_WebSite_2013/f/pdf/RPFL02VCI18.pdf. Accessed December 20, 2019.
Avoiding Accidental 
Overdoses
 According to the World Health Organization, several 
measures can be taken to avoid opioid overdose on a global 
scale:
 Increasing the availability of opioid dependence treatment, including 
for those dependent on prescription opioids 
 Reduce irrational or inappropriate prescribing of opioids 
 Closely monitoring opioid prescribing and dispensing 
 Patient education for avoiding accidental overdoses
 Never adjust your own dose – speak to your doctor if your pain is 
uncontrolled  
 If a dose is missed, do not take extra medication to make up for the 
missed dose 
 Do not mix with other medications such as benzodiazepines, 
antidepressants, cocaine) and/or alcohol
Information Sheet on Opioid Overdose. World Health Organization. https://www.who.int/substance_abuse/information-sheet/en/. Updated August 2019. Accessed December 20, 2019.
The Pharmacist’s Role
 According to the 2019 Florida statutes, Title XXIX, 
chapter 381.887: 
 “An authorized health care practitioner may prescribe and 
dispense an emergency opioid antagonist to a patient or 
caregiver for use in accordance with this section, and 
pharmacists may dispense an emergency opioid antagonist 
pursuant to such a prescription or pursuant to a non-patient-
specific standing order for an auto-injection delivery system or 
intranasal application delivery system, which must be 
appropriately labeled with instructions for use” 

Treatment Resources 
for Substance Abuse 
Treatment Resources
 Florida’s State Opioid Response Project (SOR) is administered through the 
Office of Substance Abuse and Mental Health (SAMH) in the Florida 
Department of Children and Families
 The SAMH Program is the legislatively appointed state authority for 
substance abuse, mental health, and methadone designation
Substance Abuse and Mental Health (SAMH). Florida Department of Children and Families. https://www.myflfamilies.com/service-programs/samh/. Accessed 
December 20, 2019.
https://www.myflfamilies.com/service-programs/samh/
Treatment Resources
 Follow the “Get Help” link to find local treatment programs in your area
Substance Abuse and Mental Health (SAMH). Florida Department of Children and Families. https://www.myflfamilies.com/service-programs/samh/. Accessed 
December 20, 2019.
Treatment Resources
Substance Abuse and Mental Health (SAMH). Florida Department of Children and Families. https://www.myflfamilies.com/service-programs/samh/. Accessed 
December 20, 2019.
https://www.samhsa.gov/
Take Home Points
 According to state law, C-II Rxs must be filled within 1 year 
 C-II Rxs may be faxed to the pharmacy to expedite the 
filling of a Rx, however the original Rx must be presented 
at time of dispensing 
 House Bill 21 limits quantity of CS that can be dispensed 
and requires practitioners to indicate the type of pain which 
correlates with the day supply 
 3 day supply: “acute pain”
 7 day supply: “acute pain exception”
 >7 days: “nonacute pain”
 It is the standard of practice for the Florida Board of 
Pharmacy to dispense control substance to patients with a 
valid Rx for a legitimate medical purpose
Take Home Points
 RPhs should take all necessary steps when validating an Rx 
and refuse to fill it if professional judgment concerns cannot 
be resolved as there is a corresponding responsibility when 
dispensing such prescriptions
 RPh must check E-FORCSE® for each new Rx dispensed no 
later than close of next business day
 Dispensers must notify E-FORCSE® by submitting a 
Notification of Exemption from Reporting form if they will 
not dispense CS 
 Patients with Rxs for opioids at doses >50 MME/d are at 
higher risk for overdose – this calculation should be well 
understood
 Naloxone should be dispensed to any patient who could 
possibly be experiencing an overdose – it will not have any 
adverse effects if it is given and not truly needed 
Questions
 T/F: The main purpose of House Bill 21 is to limit acute pain to seven days
 False: House Bill 21 limits Rxs according to type of pain; for acute pain the limit is a 3 
day supply. In order to get a 7 day supply, the prescriber must indicate “acute pain 
exception”
 T/F: If a prescriber does not include the required information on an Rx for a C-II CS, the 
RPh is legally allowed to confirm with the prescriber and write it on the Rx
 True
 T/F: SAMHSA is a government based helpline that provides information for Opioid 
Treatment Programs nationwide
 True
 T/F: The dose for Evzio® is 0.4 to 2 mg IV, IM, or SQ every 2-3 minutes
 False: Evzio® is the auto-injector formulation that administers 2 mg per 0.4 mL
 T/F: All formulations of naloxone can be safely disposed of by flushing them down the toilet
 False: For intranasal dosage forms, used naloxone can be discarded with other solid 
waste; for injectable dosage forms, used naloxone should be discarded in a sharps 
container
 T/F: RPhs are allowed to dispense a 3-day supply of a CS if the PDMP was not consulted
 True
Thank You!
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